ScholarIQanswers from OpenAlex
Immunitas Therapeutics (United States)
InstitutionResearch output, impact & collaborations
Immunitas Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Immunitas Therapeutics (United States)?
ScholarIQrecord summary
Immunitas Therapeutics (United States) is a research organisation in Waltham, US. OpenAlex records 29 works and 785 citations for it.
How many works does Immunitas Therapeutics (United States) have?
ScholarIQindexed works
Immunitas Therapeutics (United States) has 29 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Immunitas Therapeutics (United States) have?
ScholarIQcitation count
Immunitas Therapeutics (United States) has 785 citations in the OpenAlex counts ScholarIQ stores.
What is the average h-index at Immunitas Therapeutics (United States)?
ScholarIQavg h-index
Immunitas Therapeutics (United States) has an average h-index of 5 in OpenAlex.
What is the ROR of Immunitas Therapeutics (United States)?
ScholarIQror
The ROR for Immunitas Therapeutics (United States) is on the source record.
What is the OpenAlex record for Immunitas Therapeutics (United States)?
ScholarIQopenalex
The OpenAlex for Immunitas Therapeutics (United States) is on the source record.
Who are the most-cited researchers behind Immunitas Therapeutics (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Immunitas Therapeutics (United States)?
ScholarIQmost cited works
Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease
Richard Mayeux, Ruth Ottman, Gladys E. Maestre, Christopher Ngai, M.‐X. Tang, H N Ginsberg, Michael Chun, Benjamin Tycko, Michael L. Shelanski
A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
C.S. Kwon, Patrick Daniele, Anna Forsythe, Christopher Ngai
A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
C.S. Kwon, Patrick Daniele, Anna Forsythe, Christopher Ngai
The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States
Dominick Latrémouille-Viau, Jane Chang, Annie Guérin, Sherry Shi, Ed Wang, Justin Yu, Christopher Ngai
Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
Lauren Ramjee, Nesrin Vurgun, Christopher Ngai, Mit Patel, Gabriel Tremblay
How much of the research on Immunitas Therapeutics (United States) is open access?
ScholarIQopen access share
70%OPEN ACCESS